South Korea authorises use of Novavax COVID-19 vaccine (updated)

SK Bioscience Co

12/01/2022 04:56

(Updates with detail, context)
    SEOUL, Jan 12 (Reuters) - South Korea has authorised the use
of Novavax Inc's  NVAX.O  COVID-19 vaccine, the food and drug
safety ministry said on Wednesday. 
    South Korean vaccine developer SK Bioscience Co Ltd
 302440.KS  said it will produce the Novavax vaccine. 
    The two-dose, protein-based vaccine has secured
authorisations from European Union regulators and the World
Health Organization.  urn:newsml:reuters.com:*:nL4N2TG1U7
    It has been authorised in India, Indonesia and the
Philippines, where Novavax's partner, Serum Institute of India,
will supply it.
    Novavax is awaiting approval in Japan, where its vaccine
would be manufactured and distributed by Takeda Pharmaceutical
 4502.T . 
    South Korea has already authorised vaccines made by
AstraZeneca Inc  AZN.L , Moderna Inc  AZN.L , Pfizer  PFE.N  and
Johnson & Johnson's  JNJ.N  Janssen.   

 (Reporting by Heekyong Yang and Joyce Lee; Editing by Clarence
Fernandez)
 ((Heekyong.Yang@thomsonreuters.com;))